Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax, Glofitamab, Gemcitabine and Oxaliplatin in Relapsed/Refractory Large B-Cell Lymphoma
NCT07774234Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Aug 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sonrotoclax and glofitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Complete Response Rate at 18 weeks. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
sonrotoclaxglofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07774234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07774234.